1
|
Mensah EA, Gyasi SO, Nsubuga F, Alali WQ. A proposed One Health approach to control yellow fever outbreaks in Uganda. ONE HEALTH OUTLOOK 2024; 6:9. [PMID: 38783349 PMCID: PMC11119388 DOI: 10.1186/s42522-024-00103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 04/26/2024] [Indexed: 05/25/2024]
Abstract
Yellow Fever (YF) is an acute viral hemorrhagic disease. Uganda is located within the Africa YF belt. Between 2019 and 2022, the Ugandan Health Authorities reported at least one outbreak of YF annually with an estimated 892 suspected cases, on average per year. The persistent recurrence of this disease raises significant concerns about the efficacy of current response strategies and prevention approaches. YF has been recognized as a One Health issue due to its interrelatedness with the animal and environmental domains. Monkeys have been recognized as the virus primary reservoir. The YF virus is transmitted through bites of infected Aedes or Haemagogus species mosquitoes between monkeys and humans. Human activities, monkey health, and environmental health issues (e.g., climate change and land use) impact YF incidence in Uganda. Additionally, disease control programs for other tropical diseases, such as mosquitoes control programs for malaria, impact YF incidence.This review adopts the One Health approach to highlight the limitations in the existing segmented YF control and prevention strategies in Uganda, including the limited health sector surveillance, the geographically localized outbreak response efforts, the lack of a comprehensive vaccination program, the limited collaboration and communication among relevant national and international agencies, and the inadequate vector control practices. Through a One Health approach, we propose establishing a YF elimination taskforce. This taskforce would oversee coordination of YF elimination initiatives, including implementing a comprehensive surveillance system, conducting mass YF vaccination campaigns, integrating mosquito management strategies, and enhancing risk communication. It is anticipated that adopting the One Health approach will reduce the risk of YF incidence and outbreaks.
Collapse
Affiliation(s)
- Emmanuel Angmorteh Mensah
- Department of Biostatistics & Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA
| | - Samuel Ofori Gyasi
- Department of Immunization, Vaccines and Biologicals, World Health Organization Country Office, Kampala, Uganda
| | - Fred Nsubuga
- Division of Immunization and Vaccines, Ministry of Health, Kampala, Uganda
| | - Walid Q Alali
- Department of Biostatistics & Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA.
| |
Collapse
|
2
|
Ferrara P, Losa L, Mantovani LG, Ambrosioni J, Agüero F. Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression. J Travel Med 2024; 31:taae039. [PMID: 38438165 DOI: 10.1093/jtm/taae039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/26/2024] [Accepted: 02/28/2024] [Indexed: 03/06/2024]
Abstract
BACKGROUND Vaccination plays a critical role in mitigating the burden associated with yellow fever (YF). However, there is a lack of comprehensive evidence on the humoral response to primary vaccination in the paediatric population, with several questions debated, including the response when the vaccine is administered at early ages, the effect of co-administration with other vaccines, the duration of immunity and the use of fractional doses, among others. This study summarizes the existing evidence regarding the humoral response to primary YF vaccination in infants and children. METHODS Studies on the humoral response to primary YF vaccination in children aged 12 years or younger were reviewed. The humoral vaccine response rate (VRR), i.e. the proportion of children who tested positive for vaccine-induced YF-specific neutralizing antibodies, was pooled through random-effects meta-analysis and categorized based on the time elapsed since vaccination. Subgroup, meta-regression and sensitivity analyses were performed. RESULTS A total of 33 articles met the inclusion criteria, with all but one conducted in countries where YF is endemic. A total of 14 028 infants and children entered this systematic review. Within three months following vaccination, the pooled VRR was 91.9% (95% CI 89.8-93.9). A lower VRR was observed with the 17DD vaccine at the meta-regression analysis. No significant differences in immunogenicity outcomes were observed based on age, administration route, co-administration with other vaccines, or fractional dosing. Results also indicate a decline in VRR over time. CONCLUSIONS Primary YF vaccination effectively provides humoral immunity in paediatric population. However, humoral response declines over time, and this decline is observable after the first 18 months following vaccination. A differential response according to the vaccine substrain was also observed. This research has valuable implications for stimulating further research on the primary YF vaccination in infants and children, as well as for informing future policies.
Collapse
Affiliation(s)
- Pietro Ferrara
- Center for Public Health Research (CESP), University of Milan-Bicocca, Monza, Italy
- Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, Italy
| | - Lorenzo Losa
- Center for Public Health Research (CESP), University of Milan-Bicocca, Monza, Italy
| | - Lorenzo G Mantovani
- Center for Public Health Research (CESP), University of Milan-Bicocca, Monza, Italy
- Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, Italy
| | - Juan Ambrosioni
- Infectious Disease Department, School of Medicine, University of Barcelona, Barcelona, Spain
- HIV Unit, Infectious Diseases Service, Hospital Clinic-Fundació de Recerca Clínic Barcelon-IDIBAPS, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain
| | - Fernando Agüero
- Unit of Preventive Medicine, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
3
|
Hansen CA, Staples JE, Barrett ADT. Fractional Dosing of Yellow Fever Live Attenuated 17D Vaccine: A Perspective. Infect Drug Resist 2023; 16:7141-7154. [PMID: 38023411 PMCID: PMC10640814 DOI: 10.2147/idr.s370013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 09/20/2023] [Indexed: 12/01/2023] Open
Abstract
Yellow fever virus (YFV) is a mosquito-borne flavivirus that causes over 109,000 severe infections and over 51,000 deaths annually in endemic areas of sub-Saharan Africa and tropical South America. The virus has a transmission cycle involving mosquitoes and humans or non-human primates (NHPs) as the vertebrate hosts. Although yellow fever (YF) is prevented by a live attenuated vaccine (strain 17D), recent epidemics in Angola, the Democratic Republic of the Congo (DRC), and Brazil put great pressure on vaccine stockpiles. This resulted in the World Health Organization (WHO) and Pan American Health Organization (PAHO) implementing, on an emergency basis only, off-label dose-sparing techniques and policies during 2016-2018 to protect as many people in DRC and Brazil as possible from disease during unexpected large outbreaks of YF. Subsequently non-inferiority studies involving full doses compared to fractional doses indicated promising results, leading some policy-makers and scientists to consider utilizing YF vaccine fractional doses in non-emergency scenarios. Although the additional data on the immunogenicity and safety of fractional doses are promising, there are several questions and considerations that remain regarding the use of fractional doses, including differences in the initial antibody kinetics, differences in the immune response in certain populations, and durability of the immune response to fractional doses compared to full doses. Until the remaining knowledge gaps are addressed, full doses instead of fractional doses should continue to be used unless there are insufficient doses of the vaccine available to control outbreaks of YF.
Collapse
Affiliation(s)
- Clairissa A Hansen
- Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, 77555-4036, USA
| | - J Erin Staples
- Arboviral Diseases Branch, U.S. Centers for Disease Control and Prevention, Fort Collins, CO, USA
| | - Alan D T Barrett
- Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, 77555-4036, USA
| |
Collapse
|
4
|
Dias HG, de Lima RC, Barbosa LS, de Souza TMA, Badolato-Correa J, Maia LMS, Ferreira RDS, Neves NADS, Costa MCDS, Martins LR, de Souza EM, Carvalho MDS, de Araujo-Oliveira A, Marques WDA, Sabino-Santos G, Marques MS, de Macedo GC, Nantes WAG, Santos FM, Netto CC, Morgado TO, Bianchini MDA, Correa SHR, de Almeida JR, Campos LP, de Souza IM, Barreto WTG, Porfírio G, Alencar JAF, Herrera HM, Shlessarenko RD, da Cunha RV, de Azeredo EL, Salyer SJ, Komar N, Pauvolid-Corrêa A, dos Santos FB. Retrospective molecular investigation of Mayaro and Oropouche viruses at the human-animal interface in West-central Brazil, 2016-2018. PLoS One 2022; 17:e0277612. [PMID: 36395285 PMCID: PMC9671456 DOI: 10.1371/journal.pone.0277612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Accepted: 10/31/2022] [Indexed: 11/19/2022] Open
Abstract
Mayaro virus (MAYV, Togaviridae) and Oropouche orthobunyavirus (OROV, Peribunyaviridae) are emerging enzootic arboviruses in Latin America. Outbreaks of febrile illness associated with MAYV and OROV have been reported among humans mainly in the northern region of Brazil since the 1980s, and recent data suggest these viruses have circulated also in more populated areas of western Brazil. MAYV shares mosquito vectors with yellow fever virus and it has been historically detected during yellow fever epidemics. Aiming to investigate the transmission of OROV and MAYV at the human-animal interface during a yellow fever, chikungunya and Zika outbreaks in Brazil, we conducted a retrospective molecular investigation in 810 wild and domestic animals, 106 febrile patients, and 22.931 vectors collected from 2016 to 2018 in Cuiaba and Campo Grande metropolitan regions, western Brazil. All samples tested negative for OROV and MAYV RNA by RT-qPCR. Findings presented here suggest no active circulation of MAYV and OROV in the sampled hosts. Active surveillance and retrospective investigations are instrumental approaches for the detection of cryptic and subclinical activity of enzootic arboviruses and together serve as a warning system to implement appropriate actions to prevent outbreaks.
Collapse
Affiliation(s)
- Helver Gonçalves Dias
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
- * E-mail: (HGD); (APC)
| | - Raquel Curtinhas de Lima
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Luciana Santos Barbosa
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
- Laboratório de Genética, Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - Jessica Badolato-Correa
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Laura Marina Siqueira Maia
- Laboratório de Virologia, Faculdade de Medicina, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | - Raquel da Silva Ferreira
- Laboratório de Virologia, Faculdade de Medicina, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | | | | | - Leticia Ramos Martins
- Laboratório de Virologia, Faculdade de Medicina, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | - Emerson Marques de Souza
- Laboratório de Virologia, Faculdade de Medicina, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | | | | | | | - Gilberto Sabino-Santos
- Center for Virology Research, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto-SP, Brazil
- Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans-LA, United States of America
| | - Marcio Schafer Marques
- Center for Virology Research, Ribeirão Preto Medical School University of São Paulo, Ribeirão Preto-SP, Brazil
| | - Gabriel Carvalho de Macedo
- Laboratório de Biologia Parasitária, Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Brazil
| | - Wesley Arruda Gimenes Nantes
- Laboratório de Biologia Parasitária, Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Brazil
| | - Filipe Martins Santos
- Laboratório de Biologia Parasitária, Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Brazil
| | | | | | | | | | - Júlia Ramos de Almeida
- Faculdade de Medicina Veterinária, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | - Larissa Pratta Campos
- Faculdade de Medicina Veterinária, Universidade Federal de Mato Grosso (UFMT), Cuiabá, Brazil
| | | | - Wanessa Teixeira Gomes Barreto
- Laboratório de Ecologia de Populações e do Movimento, Programa de Ecologia e Conservação, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - Grasiela Porfírio
- Laboratório de Biologia Parasitária, Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Brazil
| | | | - Heitor Miraglia Herrera
- Laboratório de Biologia Parasitária, Programa de Pós-Graduação em Ciências Ambientais e Sustentabilidade Agropecuária, Universidade Católica Dom Bosco, Campo Grande, Brazil
- Laboratório de Ecologia de Populações e do Movimento, Programa de Ecologia e Conservação, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | | | - Rivaldo Venancio da Cunha
- Fiocruz, Campo Grande, Mato Grosso do Sul, Brazil
- Departamento de Clínica Médica, Universidade Federal do Mato Grosso do Sul, Campo Grande (UFMS), Campo Grande, Brazil
| | - Elzinandes Leal de Azeredo
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Stephanie J. Salyer
- Division of Global Health Protection, Center for Global Health, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
| | - Nicholas Komar
- Arboviral Diseases Branch, Division of Vector-borne Diseases, U.S. Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado, United States of America
| | - Alex Pauvolid-Corrêa
- Departamento de Veterinária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
- * E-mail: (HGD); (APC)
| | - Flávia Barreto dos Santos
- Laboratório de Imunologia Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| |
Collapse
|
5
|
Re-emergence of yellow fever in the neotropics - quo vadis? Emerg Top Life Sci 2021; 4:399-410. [PMID: 33258924 PMCID: PMC7733675 DOI: 10.1042/etls20200187] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/05/2020] [Accepted: 11/09/2020] [Indexed: 02/02/2023]
Abstract
Yellow fever virus (YFV) is the etiological agent of yellow fever (YF), an acute hemorrhagic vector-borne disease with a significant impact on public health, is endemic across tropical regions in Africa and South America. The virus is maintained in two ecologically and evolutionary distinct transmission cycles: an enzootic, sylvatic cycle, where the virus circulates between arboreal Aedes species mosquitoes and non-human primates, and a human or urban cycle, between humans and anthropophilic Aedes aegypti mosquitoes. While the urban transmission cycle has been eradicated by a highly efficacious licensed vaccine, the enzootic transmission cycle is not amenable to control interventions, leading to recurrent epizootics and spillover outbreaks into human populations. The nature of YF transmission dynamics is multifactorial and encompasses a complex system of biotic, abiotic, and anthropogenic factors rendering predictions of emergence highly speculative. The recent outbreaks in Africa and Brazil clearly remind us of the significant impact YF emergence events pose on human and animal health. The magnitude of the Brazilian outbreak and spillover in densely populated areas outside the recommended vaccination coverage areas raised the specter of human — to — human transmission and re-establishment of enzootic cycles outside the Amazon basin. Herein, we review the factors that influence the re-emergence potential of YFV in the neotropics and offer insights for a constellation of coordinated approaches to better predict and control future YF emergence events.
Collapse
|
6
|
Cracknell Daniels B, Gaythorpe K, Imai N, Dorigatti I. Yellow fever in Asia-a risk analysis. J Travel Med 2021; 28:taab015. [PMID: 33506250 PMCID: PMC8045179 DOI: 10.1093/jtm/taab015] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 01/19/2021] [Accepted: 01/20/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND There is concern about the risk of yellow fever (YF) establishment in Asia, owing to rising numbers of urban outbreaks in endemic countries and globalisation. Following an outbreak in Angola in 2016, YF cases were introduced into China. Prior to this, YF had never been recorded in Asia, despite climatic suitability and the presence of mosquitoes. An outbreak in Asia could result in widespread fatalities and huge economic impact. Therefore, quantifying the potential risk of YF outbreaks in Asia is a public health priority. METHODS Using international flight data and YF incidence estimates from 2016, we quantified the risk of YF introduction via air travel into Asia. In locations with evidence of a competent mosquito population, the potential for autochthonous YF transmission was estimated using a temperature-dependent model of the reproduction number and a branching process model assuming a negative binomial distribution. RESULTS In total, 25 cities across Asia were estimated to be at risk of receiving at least one YF viraemic traveller during 2016. At their average temperatures, we estimated the probability of autochthonous transmission to be <50% in all cities, which was primarily due to the limited number of estimated introductions that year. CONCLUSION Despite the rise in air travel, we found low support for travel patterns between YF endemic countries and Asia resulting in autochthonous transmission during 2016. This supports the historic absence of YF in Asia and suggests it could be due to a limited number of introductions in previous years. Future increases in travel volumes or YF incidence can increase the number of introductions and the risk of autochthonous transmission. Given the high proportion of asymptomatic or mild infections and the challenges of YF surveillance, our model can be used to estimate the introduction and outbreak risk and can provide useful information to surveillance systems.
Collapse
Affiliation(s)
- Bethan Cracknell Daniels
- MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London
| | - Katy Gaythorpe
- MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London
| | - Natsuko Imai
- MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London
| | - Ilaria Dorigatti
- MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London
| |
Collapse
|
7
|
Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. Viruses 2020; 12:v12111300. [PMID: 33198381 PMCID: PMC7697718 DOI: 10.3390/v12111300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 10/27/2020] [Accepted: 11/09/2020] [Indexed: 12/13/2022] Open
Abstract
Yellow fever virus (YFV) is a mosquito-borne member of the genus flavivirus, including other important human-pathogenic viruses, such as dengue, Japanese encephalitis, and Zika. Herein, we report identifying 129 YFV Class II epitopes in donors vaccinated with the live attenuated YFV vaccine (YFV-17D). A total of 1156 peptides predicted to bind 17 different common HLA-DRB1 allelic variants were tested using IFNγ ELISPOT assays in vitro re-stimulated peripheral blood mononuclear cells from twenty-six vaccinees. Overall, we detected responses against 215 YFV epitopes. We found that the capsid and envelope proteins, as well as the non-structural (NS) proteins NS3 and NS5, were the most targeted proteins by CD4+ T cells from YF-VAX vaccinated donors. In addition, we designed and validated by flow cytometry a CD4+ mega pool (MP) composed of structural and non-structural epitopes in an independent cohort of vaccinated donors. Overall, this study provides a comprehensive prediction and validation of YFV epitopes in a cohort of YF-17D vaccinated individuals. With the design of a CD4 epitope MP, we further provide a useful tool to detect ex vivo responses of YFV-specific CD4 T cells in small sample volumes.
Collapse
|
8
|
Bifani AM, Ong EZ, de Alwis R. Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever. CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES 2020; 12:398-409. [PMID: 33173445 PMCID: PMC7644428 DOI: 10.1007/s40506-020-00237-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/20/2020] [Indexed: 12/24/2022]
Abstract
At the turn of the nineteenth century, yellow fever (YF) was considered the most dangerous infectious disease with high case fatality. Subsequent, mass vaccination campaigns coupled with widespread elimination of the YF mosquito vector significantly decreased YF cases and reduced outbreaks to the tropical and subtropical forested regions of Africa and South America. However, recent (2016) large outbreaks in Angola, Democratic Republic of Congo (DRC), and South-Eastern Brazil, where previously had been demarcated as low-risk regions, have highlighted the possibility of a rapidly changing epidemiology and the potential re-emergence of yellow fever virus (YFV). Furthermore, the first-ever importation of YFV into Asia has highlighted the potential fear of YFV emerging as a global threat. In this review, we describe the changing epidemiology of YF outbreaks, and highlight the use of public health policies, therapeutics, and vaccination as tools to help eliminate future YFV outbreaks.
Collapse
Affiliation(s)
- Amanda Makha Bifani
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
| | - Eugenia Z. Ong
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
- Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (VIREMiCS), Singapore, Singapore
| | - Ruklanthi de Alwis
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
- Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (VIREMiCS), Singapore, Singapore
| |
Collapse
|
9
|
Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever. CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES 2020; 12:349-360. [PMID: 32837338 PMCID: PMC7351566 DOI: 10.1007/s40506-020-00232-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Purpose of Review At the turn of the nineteenth century, yellow fever (YF) was considered the most dangerous infectious disease with high case fatality. Subsequent, mass vaccination campaigns coupled with widespread elimination of the YF mosquito vector significantly decreased YF cases and reduced outbreaks to the tropical and subtropical forested regions of Africa and South America. Recent Findings However, recent (2016) large outbreaks in Angola, Democratic Republic of Congo (DRC), and South-Eastern Brazil, where previously had been demarcated as low-risk regions, have highlighted the possibility of a rapidly changing epidemiology and the potential re-emergence of yellow fever virus (YFV). Furthermore, the first-ever importation of YFV into Asia has highlighted the potential fear of YFV emerging as a global threat. Summary In this review, we describe the changing epidemiology of YF outbreaks and highlight the use of public health policies, therapeutics, and vaccination as tools to help eliminate future YFV outbreaks.
Collapse
|
10
|
Olson MF, Ndeffo-Mbah ML, Juarez JG, Garcia-Luna S, Martin E, Borucki MK, Frank M, Estrada-Franco JG, Rodríguez-Pérez MA, Fernández-Santos NA, Molina-Gamboa GDJ, Carmona Aguirre SD, Reyes-Berrones BDL, Cortés-De la cruz LJ, García-Barrientos A, Huidobro-Guevara RE, Brussolo-Ceballos RM, Ramirez J, Salazar A, Chaves LF, Badillo-Vargas IE, Hamer GL. High Rate of Non-Human Feeding by Aedes aegypti Reduces Zika Virus Transmission in South Texas. Viruses 2020; 12:E453. [PMID: 32316394 PMCID: PMC7232486 DOI: 10.3390/v12040453] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 04/13/2020] [Accepted: 04/14/2020] [Indexed: 12/21/2022] Open
Abstract
Mosquito-borne viruses are emerging or re-emerging globally, afflicting millions of people around the world. Aedes aegypti, the yellow fever mosquito, is the principal vector of dengue, Zika, and chikungunya viruses, and has well-established populations across tropical and subtropical urban areas of the Americas, including the southern United States. While intense arboviral epidemics have occurred in Mexico and further south in the Americas, local transmission in the United States has been minimal. Here, we study Ae. aegypti and Culex quinquefasciatus host feeding patterns and vertebrate host communities in residential environments of South Texas to identify host-utilization relative to availability. Only 31% of Ae. aegypti blood meals were derived from humans, while 50% were from dogs and 19% from other wild and domestic animals. In Cx. quinquefasciatus, 67% of blood meals were derived from chicken, 22% came from dogs, 9% from various wild avian species, and 2% from other mammals including one human, one cat, and one pig. We developed a model for the reproductive number, R0, for Zika virus (ZIKV) in South Texas relative to northern Mexico using human disease data from Tamaulipas, Mexico. We show that ZIKV R0 in South Texas communities could be greater than one if the risk of human exposure to Ae. aegypti bites in these communities is at least 60% that of Northern Mexico communities. The high utilization of non-human vertebrates and low risk of human exposure in South Texas diminishes the outbreak potential for human-amplified urban arboviruses transmitted by Ae. aegypti.
Collapse
Affiliation(s)
- Mark F. Olson
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| | - Martial L. Ndeffo-Mbah
- Veterinary Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA;
| | - Jose G. Juarez
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| | - Selene Garcia-Luna
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| | - Estelle Martin
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| | - Monica K. Borucki
- Biosciences and Biotechnology Division, Chemistry, Materials and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA; (M.K.B.); (M.F.)
| | - Matthias Frank
- Biosciences and Biotechnology Division, Chemistry, Materials and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA; (M.K.B.); (M.F.)
| | - José Guillermo Estrada-Franco
- Instituto Politécnico Nacional, Centro de Biotecnología Genómica, Cd. Reynosa 88710, Tamaulipas, Mexico; (J.G.E.-F.); (M.A.R.-P.); (N.A.F.-S.)
| | - Mario A. Rodríguez-Pérez
- Instituto Politécnico Nacional, Centro de Biotecnología Genómica, Cd. Reynosa 88710, Tamaulipas, Mexico; (J.G.E.-F.); (M.A.R.-P.); (N.A.F.-S.)
| | - Nadia A. Fernández-Santos
- Instituto Politécnico Nacional, Centro de Biotecnología Genómica, Cd. Reynosa 88710, Tamaulipas, Mexico; (J.G.E.-F.); (M.A.R.-P.); (N.A.F.-S.)
| | - Gloria de Jesús Molina-Gamboa
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Santos Daniel Carmona Aguirre
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Bernardita de Lourdes Reyes-Berrones
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Luis Javier Cortés-De la cruz
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Alejandro García-Barrientos
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Raúl E. Huidobro-Guevara
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Regina M. Brussolo-Ceballos
- Secretary of Health of the State of Tamaulipas, Epidemiology Directorate, Cd. Victoria 87000, Tamaulipas, Mexico; (G.d.J.M.-G.); (S.D.C.A.); (B.d.L.R.-B.); (L.J.C.-D.l.c.); (A.G.-B.); (R.E.H.-G.); (R.M.B.-C.)
| | - Josue Ramirez
- Health Department, City of Harlingen, TX 78550, USA;
| | - Aaron Salazar
- Hidalgo County Health & Human Services, Edinburg, TX 78539, USA;
| | - Luis F. Chaves
- Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (INCIENSA), Apartado Postal, Tres Ríos, Cartago 4-2250, Costa Rica;
| | - Ismael E. Badillo-Vargas
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| | - Gabriel L. Hamer
- Department of Entomology, Texas A&M University, College Station, TX 77843, USA; (M.F.O.); (J.G.J.); (S.G.-L.); (E.M.); (I.E.B.-V.)
| |
Collapse
|
11
|
Barrett ADT. Yellow Fever Vaccine: The Conundrum of 2 Doses, One Dose, or One-Fifth Dose to Induce and Maintain Protective Immunity. J Infect Dis 2019; 221:1922-1924. [DOI: 10.1093/infdis/jiz379] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 07/16/2019] [Indexed: 11/12/2022] Open
Affiliation(s)
- Alan D T Barrett
- Department of Pathology and Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston
| |
Collapse
|